Preferred Label : Asenapine;
MeSH note : an antipsychotic agent;
CISMeF synonym : saphris;
MeSH synonym : trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole;
MeSH hyponym : 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole; ORG-5222; ORG 5222; Saphris;
MeSH Related Number : asenapine maleate; CU9463U2E2;
Related CAS MeSH : CU9463U2E2 (asenapine maleate);
Is substance : O;
UNII : JKZ19V908O;
InChIKey : VSWBSWWIRNCQIJ-HUUCEWRRSA-N;
Origin ID : C522667;
UMLS CUI : C2000088;
ATC code(s)
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
Manual BTNT mappings - CISMeF
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61455009
2012
France
summary of product characteristics
Asenapine
maleates
sublingual gland
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=65697814
2012
France
summary of product characteristics
maleates
Asenapine
tablets
sublingual gland
---
Summary Basis of Decision (SBD) for Saphris
Asenapine, as asenapine maleate, 5 mg and 10 mg, Tablet, Sublingual
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00133
2012
false
Canada
French
English
asenapine maleate
asenapine maleate
drug information
Product containing precisely asenapine 5 milligram/1 each conventional release sublingual
tablet (clinical drug)
Product containing precisely asenapine 10 milligram/1 each conventional release sublingual
tablet (clinical drug)
administration, sublingual
Heterocyclic Compounds, 4 or More Rings
Heterocyclic Compounds, 4 or More Rings
Asenapine
Asenapine
asenapine
drug approval
treatment outcome
risk assessment
adult
antipsychotic agents
antipsychotic agents
schizophrenia
bipolar disorder
drug therapy, combination
aged
receptors, dopamine d2
receptor, serotonin, 5-ht2a
randomized controlled trials as topic
---
https://www.ema.europa.eu/medicines/human/EPAR/Sycrest
2012
false
United Kingdom
French
English
asenapine maleate
asenapine maleate
syndication feed
Asenapine
Asenapine
drug approval
treatment outcome
administration, sublingual
adult
antipsychotic agents
Heterocyclic Compounds, 4 or More Rings
antipsychotic agents
Heterocyclic Compounds, 4 or More Rings
bipolar disorder
asenapine
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
summary of product characteristics
drug evaluation
package leaflet
---
http://www.has-sante.fr/portail/jcms/c_1213139/sycrest-asenapine-antipsychotique-synthese-d-avis
2011
false
France
French
guidelines for drug use
evaluation of the transparency committee
asenapine maleate
asenapine maleate
Heterocyclic Compounds, 4 or More Rings
Heterocyclic Compounds, 4 or More Rings
administration, sublingual
Asenapine
bipolar disorder
antipsychotic agents
asenapine
insurance, health, reimbursement
adult
treatment outcome
clinical trials as topic
Asenapine
antipsychotic agents
drug therapy, combination
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-12/sycrest_2-11-2011_avis_ct-11050.pdf
http://www.has-sante.fr/portail/jcms/c_1146484/sycrest
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/sycrest_ct_11050.pdf
2011
false
France
French
English
evaluation of the transparency committee
asenapine maleate
asenapine maleate
Asenapine
asenapine
Heterocyclic Compounds, 4 or More Rings
antipsychotic agents
administration, sublingual
insurance, health, reimbursement
bipolar disorder
treatment outcome
adult
randomized controlled trials as topic
Asenapine
antipsychotic agents
Heterocyclic Compounds, 4 or More Rings
---